GlobeNewsWire
28 May 2026, 02:28 UTC · 2h ago
Source · https://www.globenewswire.com/news-release/2026/05/28/3302489/673/en/ROSEN-A-RANKED-AND-LEADING-FIRM-Encourages-Immutep-Ltd-Investors-to-Secure-Counsel-Before-Important-Deadline-in-Securities-Class-Action-IMMP.html
Read source
Story key points
2 claims · impact-rated
Immutep Ltd. is facing a securities class action lawsuit alleging the company made false or misleading statements regarding the TACTI-004 clinical trial. — Allegations of misleading clinical trial data and securities fraud typically lead to investor distrust and downward pressure on biotech stock prices.
-0.60The lawsuit claims Immutep concealed internal data suggesting a material risk that the TACTI-004 study would fail to meet primary efficacy and safety endpoints. — The potential failure of a key clinical trial is a material fundamental risk that directly impacts the valuation of a pharmaceutical company's pipeline.
-0.50Ticker attribution
Model heads
The company is being targeted by a securities class action lawsuit by the Rosen Law Firm.
Search tags
The company is facing a securities class action lawsuit alleging false and misleading statements regarding clinical trial data.
The company is being targeted by a securities class action lawsuit by the Rosen Law Firm.
No ticker relationship head found.
Impact vectors
1 dimensions · 9 clusters
Market reaction
0 bid · 10 offered
No stock impact ranking available yet.
